INVITRO ACTIVITY, PHARMACOKINETICS, CLINICAL SAFETY AND THERAPEUTIC EFFICACY OF ENOXACIN IN THE TREATMENT OF PATIENTS WITH COMPLICATED URINARY-TRACT INFECTIONS

被引：10

作者：

NABER, KG

SORGEL, F

GUTZLER, F

BARTOSIKWICH, B

机构：

[1] CARL KORTH INST,D-8520 ERLANGEN,FED REP GER

[2] UNIV HEIDELBERG,MED KLIN,D-6900 HEIDELBERG,FED REP GER

来源：

INFECTION | 1985年 / 13卷 / 05期

关键词：

D O I：

10.1007/BF01667215

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：219 / 224

页数：6

共 15 条

[1]

ADHAMI Z, 1983, J ANTIMICROB CHEMOTH, V13, P87

[2] INVITRO ACTIVITY OF ENOXACIN, A QUINOLONE CARBOXYLIC-ACID, COMPARED WITH THOSE OF NORFLOXACIN, NEW BETA-LACTAMS, AMINOGLYCOSIDES, AND TRIMETHOPRIM [J].

CHIN, NX ;

NEU, HC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 24 (05) :754-763

[3] PHARMACOKINETICS AND TISSUE PENETRATION OF CIPROFLOXACIN [J].

CRUMP, B ;

WISE, R ;

DENT, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 24 (05) :784-786

[4] SERUM AND SPUTUM CONCENTRATIONS OF ENOXACIN AFTER SINGLE ORAL DOSING IN A CLINICAL AND BACTERIOLOGICAL STUDY [J].

DAVIES, BI ;

MAESEN, FPV ;

TEENGS, JP .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1984, 14 :83-89

[5]

GUTZLER F, 1984, FORTSCHR ANTIMIKR AN, V3, P673

[6]

HEINZEL G, 1982, PHARMACOKINETICS DRU, P207

[7]

NABER K, 1983, MUNCHEN MED WOCHEN, V125, P423

[8]

NABER K, 1983, Z ANTIMIKR ANTINEOPL, V1, P41

[9]

NABER K, 1984, FORTSCHR ANTIMIKR AN, V3, P749

[10]

Naber K, 1984, FORTSCHR ANTIMIKR AN, V3, P701

← 1 2 →